Levofloxacin-containing Triple and Sequential Therapy or Standard Sequential Therapy as the First Line Treatment for Helicobacter pylori Eradication in China

Helicobacter

Volumn 17, Issue 6, 2012, Pages 478-485

  Qian, Juan ^a   Ye, Feng ^a   Zhang, Jun ^a   Yang, Yan Mei ^b   Tu, Hui Ming ^c   Jiang, Qi ^d   Shang, Li ^a   Pan, Xiao Lin ^a   Shi, Rui Hua ^a   Zhang, Guo Xin ^e  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b The First People's Hospital of Nantong   (China)

^c Soochow University   (China)

^d People's Hospital of Dongtai County   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Helicobacter pylori; Levofloxacin; Sequential therapy; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; TINIDAZOLE;

ADULT; AGED; ARTICLE; BITTER TASTE; CHEST DISTRESS; CHICKENPOX; CHINA; CONTROLLED STUDY; DIARRHEA; DISTRESS SYNDROME; DRUG EFFICACY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HEADACHE; HEART PALPITATION; HELICOBACTER INFECTION; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UREA BREATH TEST;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BREATH TESTS; CHINA; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84867695557     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00993.x     Document Type: Article

References (59)

1. Blaser MJ, Atherton JC. Helicobacter pylori persistence: biology and disease. J Clin Invest 2004;113:321-333.
2. Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, Oak JH, Jung SH. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: A double-blind, randomized controlled trial. J Korean Med Sci 2011;26:785-90.
3. Minakari M, Davarpanah Jazi AH, Shavakhi A, Moghareabed N, Fatahi F. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection. Helicobacter 2010;15:154-9.
4. Cetinkaya ZA, Sezikli M, Güzelbulut F, Coşgun S, Düzgün S, Kurdaş OO. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin. Helicobacter 2010;15:143-7.
5. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
6. Harvey RF, Lane JA, Nair P, Egger M, Harvey I, Donovan J, Murray L. Clinical trial: the prolonged beneficial effect of Helicobacter pylori eradication on dyspepsia consultations - the Bristol Helicobacter Project. Aliment Pharmacol Ther 2010;32:394-400.
7. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori time to consider making the switch? JAMA 2008;300:1346-47.
8. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138-44.
9. Hiraishi H, Haruma K, Miwa H, Goto H. Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection - the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 2010;31:824-33.
10. Hung IF, Chan P, Leung S, et al. Clarithromycin-amoxycillin-containing triple therapy: A valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009;14:505-11.
11. Antos D, Schneider-Brachert W, Bästlein E, et al. 7-day triple therapy of Helicobacter pylori infection with Levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006;11:39-45.
12. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
13. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000;19:538-41.
14. Miehlke S, Kirsch C, Schneider-Brachert W, et al. Treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin - a randomized trial comparing high-dose omeprazole/amoxicillin therapy and quadruple therapy. Helicobacter 2003;8:310-9.
15. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002;7:306-9.
16. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161:1217-20.
17. Liang X, Liu WZ, Lu H, Xu WW, Xiao SD. Helicobacter pylori: in vitro induction of resistance to antibiotics and surveillance of its resistant prevalence. Chin J Dig March 2003;23:146-9.
18. Cheng H, Hu FL, Zhang GX, Shi RH, Du YQ, Li ZS, Han W, Li YQ, Wu QD, Qian KD. Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multicentral, randomized, controlled clinical study. Natl Med J China 2010;90:79-82.
19. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. Ann Intern Med 2007;146:556-63.
20. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.
21. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
22. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24.
23. Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 2006;101:185-90.
24. Gisbert JP, Fernández-Bermejo M, Molina-Infante J, Pérez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodríguez JM, Robledo-Andrés P, González-García G. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;26:495-500.
25. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70.
26. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45-9.
27. Yu C, Li L, Chen W, Jiao Y, Yang N, Yang E, Zhang J, Chen L, Li Y. Levofloxacin susceptibility testing for Helicobacter pylori in China: comparison of E-test and disk diffusion method. Helicobacter 2011;16:119-23.
28. Tan HL, Liu B, Liu TM, Wang YF, Yin DM, Zhou XQ. Study on antibiotic resistance of Helicobacter pylori isolated in Qingpu District, Shanghai. Chin J Gastroenterol 2011;16:32-5.
29. Zhou Y, Xu XL, Wang CP, Zhou M, Zeng XH. Detection and the antibiotic susceptibility analysis of mycoplasma and chlamydia in urogenital tract infections of 327 cases patients with tubal infertility. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011;25:201-4.
30. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS ONE 2012;7:e32976.
31. Wang H, Liu YL, Chen MJ, et al. Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010. Zhonghua Jie He He Hu Xi Za Zhi 2012;35:113-9.
32. Hao H, Yang B, Shi J, Xi M, Wang X, Cui Y, Meng J. Drug resistance and related genes of chickenborne Salmonella to quinolone and fluoroquinolones. Wei Sheng Wu Xue Bao 2011;51:1413-20.
33. Wang H, Chen M, Xu Y, et al. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. Int J Antimicrob Agents 2011;38:376-83.
34. Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol 2012; Feb 2. [Epub ahead of print].
35. Song W, Cao J, Mei YL. Correlation between cephamycin consumption and the incidence of antimicrobial resistance in Acinetobacter baumannii at a university hospital in China from 2001 to 2009. Int J Clin Pharmacol Ther 2011;49:765-71.
36. Zhang R, Sun Q, Hu YJ, et al. Detection of the Smqnr quinolone protection gene and its prevalence in clinical isolates of Stenotrophomonas maltophilia in China. J Med Microbiol 2012;61(Pt 4):535-39.
37. Yu HT, Wang Q, Yang N, Li HM, Liang JQ, Liu CH. Risk factors associated with kanamycin-resistant tuberculosis in a Beijing tuberculosis referral hospital. J Med Microbiol 2012;61(Pt 7):960-7.
38. 13C-urea breath test maintain a satisfactory accuracy in diagnosing Helicobacter pylori infection? Arq Gastroenterol 2011;48:104-8.
39. Wong WM, Wong BC, Wong KW, et al. (13)C-urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2000;14:1353-58.
40. Coelho LG, Reber M, Passos MC, et al. Application of isotope-selective non-dispersive infrared spectrometry for the evaluation of 13 C-urea breath test: comparison with three concordant methods. Braz J Med Biol Res 1999;32:1493-97.
41. Pan X, Li Y, Qiu Y, Tang Q, Ni J, Shi R, Zhang G. Efficacy and Tolerability of First-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori Infection and the effect of CYP2C19 genotype: A 1-week, randomized, open-label study in Chinese adults. Clin Ther 2010;32:2003-11.
42. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis. Am J Gastroenterol 2009;104:3069-79.
43. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41-53.
44. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either seven-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006;20:113-7.
45. McLoughlin RM, O'Morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol 2005;19:421-7.
46. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter 2009;14:520-4.
47. Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011;66:1847-52.
48. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadia EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;31:1077-84.
49. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:1339-43.
50. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009;67:96-101.
51. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-based concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143(1):55-61. e1.
52. Ozdil K, Calhan T, Sahin A, Senates E, Kahraman R, Yüzbasioglu B, Demirdag H, Demirsoy H, Sökmen MH. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011;58:1148-52.
53. Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M. Efficacy and safety of levofloxacin, Clarithromycin and esomeprazole as first line triple therapy or Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med 2010;1:10-14.
54. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole J Clin Gastroenterol 2006;40:515-20.
55. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16:5118-21.
56. Wang F, Shen SR, Zhou JD, Xu CX. Antibiotic resistance of Helicobacter pylori. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2007;32:447-50.
57. Pan ZJ, Su WW, Tytgat GN, Dankert J, Van der Ende A. Assessment of clarithromycin-resistant Helicobacter pylori among patients in Shanghai and Guangzhou, China, by primer-mismatch PCR. J Clin Microbiol 2002;40:259-61.
58. Wang WH, Wong BC, Mukhopadhyay AK, Berg DE, Cho CH, Lai KC, Hu WH, Fung FM, Hui WM, Lam SK. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000;14:901-10.
59. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000;46:121-3.